What is the equity of Pharma Mar this year?
Pharma Mar has equity of 193.44 M EUR this year.
Pharma Mar Equity 2024
Pharma Mar Equity
193.44 M EUR
Pharma Mar Dividend yield
1.71 %
Ticker
PHM.MC
ISIN
ES0169501022
WKN
A2P9YT
In 2024, Pharma Mar's equity was 193.44 M EUR, a -13.24% increase from the 222.96 M EUR equity in the previous year.
Pharma Mar Aktienanalyse
What does Pharma Mar do?
Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Pharma Mar's Equity
Pharma Mar's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Pharma Mar's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Pharma Mar's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Pharma Mar's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Pharma Mar’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Pharma Mar Stock
What was the equity of Pharma Mar compared to the previous year?
The equity of Pharma Mar has increased/decreased by -13.24% decreased compared to the previous year.
What impact does a high equity have on investors of Pharma Mar?
A high equity is advantageous for investors of Pharma Mar as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Pharma Mar?
A low equity can be a risk for investors of Pharma Mar, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Pharma Mar affect the company?
An increase in equity of Pharma Mar can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Pharma Mar affect the company?
A reduction in equity of Pharma Mar can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Pharma Mar?
Some factors that can affect the equity of Pharma Mar include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Pharma Mar so important for investors?
The equity of Pharma Mar is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Pharma Mar take to change the equity?
To change equity, Pharma Mar can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Pharma Mar pay?
Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.71 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.
What is the dividend yield of Pharma Mar?
The current dividend yield of Pharma Mar is 1.71 %.
When does Pharma Mar pay dividends?
Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.
How secure is the dividend of Pharma Mar?
Pharma Mar paid dividends every year for the past 9 years.
What is the dividend of Pharma Mar?
For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 2.02 %.
In which sector is Pharma Mar located?
Pharma Mar is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.
When did Pharma Mar pay the last dividend?
The last dividend was paid out on 6/14/2024.
What was the dividend of Pharma Mar in the year 2023?
In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.
In which currency does Pharma Mar pay out the dividend?
The dividends of Pharma Mar are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharma Mar
Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
